TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02950584

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Titanium dioxide denture
Description: Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titanium dioxide denture
Description: Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rapid heat denture
Description: Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid heat denture
Description: Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
Study: NCT02595710

Intervention type: OTHER
Intervention: skin punch biopsy collection
Description: Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.

Intervention type: OTHER
Intervention: Blood collection
Description: Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.

Intervention type: OTHER
Intervention: Urine sample collection
Description: Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
Study: NCT03560596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Intervention
Description: 9 sessions with bilingual health coaches who will utilize a culturally tailored adherence checklist to identify patients specific medication adherence barriers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: standard hypertension treatment recommendations as determined by PCP
Study: NCT02565472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White grape juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple juice
Study: NCT01442636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: Implantation of one or more Everolimus-eluting XIENCE PRIME™ Everolimus Eluting Coronary Stent Systems.
Study: NCT04548128

Intervention type: DEVICE
Intervention: HeartMate 3 Left Ventricular Assist System (HM3 LVAS)
Description: This clinical trial investigates implant of the HM3 LVAS by techniques other than full median sternotomy.
Study: NCT04504760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2910
Description: Single ascending dose of ONO-2910 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2910
Description: Multiple ascending dose of ONO-2910 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose of placebo will be administered orally.
Study: NCT04190095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motion Tracking in VR
Description: Participant will wear motion sensors and VR devices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Interaction
Description: Participant will perform VR interaction task
Study: NCT02669537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GoPro Camera
Description: The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GoPro Camera
Description: The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.
Study: NCT01197235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin-α
Description: Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: Infusion of isotonic saline will be performed 1 hour before angiography
Study: NCT00538538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy with subretinal lucentis
Description: A gas bubble will be placed in the eye after the gel has been removed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy with subretinal lucentis
Description: These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
Study: NCT01086475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
Study: NCT02580344

Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
Study: NCT03331562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: pembrolizumab solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: pembrolizumab solution for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: Paricalcitol solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline solution for injection
Study: NCT04328285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Hydroxychloroquine
Description: Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir and ritonavir
Description: LPV/r Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of LPV/r Tablets
Description: Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets
Study: NCT00167947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamune (Sirolimus)
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune (Sirolimus)
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped
Study: NCT00327808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI-1020
Description: 600 mcg BID x 14 days followed by 1200 mcg BID x 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: 400 mcg BID x 14 days then 800 mcg/day x 7 more days
Study: NCT03402087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study: NCT00517062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth hormone (Genotropin)
Description: Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo self-injected once a day subcutaneously at bedtime.
Study: NCT04025840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (10 mg) is administered intravenously before anesthesia induction.
Study: NCT04093700

Intervention type: DEVICE
Intervention: SureLock All-Suture Anchor
Description: Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
Study: NCT02289378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Oxaliplatin and 5-Fu
Description: To investigate the triplet regimen in the first-line therapy of advanced chemotherapy
Study: NCT03308851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocorticision
Description: The piezocorticision is a procedure that aims to accelerate the movement of teeth during an orthodontic treatment. It consists of a local anaesthesia followed by an incision of the buccal mucosa and an incision in the alveolar bone with a piezotome.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteoperforation
Description: The osteoperforation is a procedure that aims to accelerate the movement of teeth during orthodontic treatment. It consists of a local anaesthesia followed by perforations of the buccal mucosa and alveolar bone using a specific osteoperforation tool.
Study: NCT01173653

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation
Description: Randomly introducing patients to a Department of Health program to help them quit smoking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
Study: NCT00454233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM543
Description: Oral
Study: NCT02400580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: The patients in the treatment arm will receive 1000mg of IV acetaminophen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patients in the placebo arm will receive normal saline.
Study: NCT03246854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR112
Description: DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.
Study: NCT02746380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBAL
Description: Adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira®
Description: Adalimumab
Study: NCT00454233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM543
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM543
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM543
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01697332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129Xe gas
Description: 800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
Study: NCT02286102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPAT
Description: OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Constavac
Description: Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively
Study: NCT04400500

Intervention type: DIAGNOSTIC_TEST
Intervention: Approaches to differential diagnosis and risk stratification
Description: Detailed analysis of clinical course, ECG, biomarkers (hsTn I, CK-MB mass, myoglobin, NT-proBNP, hsCPR, cardiac FABP on admission and after 3 hours; hsTn I, CK-MB mass and myoglobin after 6 hours if needed) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores.
Study: NCT04184648

Intervention type: OTHER
Intervention: no interventions
Description: no intervention

Intervention type: OTHER
Intervention: no interventions
Description: no intervention
Study: NCT03547141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01
Description: injection of MBA-P01 into the muscle of each contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01
Description: injection of MBA-P01 into the muscle of each contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01
Description: injection of MBA-P01 into the muscle of each contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01
Description: injection of MBA-P01 into the muscle of each contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: injection of BOTOX into the muscle of each contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: injection of BOTOX into the muscle of each contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: injection of BOTOX into the muscle of each contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: injection of BOTOX into the muscle of each contralateral foot in equal doses
Study: NCT04735029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal gun
Description: Thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heat pack
Description: A hydrocollator heat pack used to simulate traditional thermal therapy
Study: NCT01917331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone/Formoterol/Glycopyrrolate
Description: Active drug tested

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone/Formoterol
Description: Active comparator
Study: NCT02646904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Beclomethasone Dipropionate
Description: Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CERCHIO 10 mg/ml OS
Description: For Children \< 12 years old 10 drops die (5 mg die) for 21 days. For Children \> 12 years old 20 drops die (10 mg die) for 21 days.
Study: NCT00954785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle brace
Description: Sports Stirrup ankle brace (Aircast)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle brace
Description: Sports Stirrup ankle brace (Aircast)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ankle brace
Description: Sports Stirrup ankle brace (Aircast)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac 50 mg tds
Description: In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg mane
Description: In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
Study: NCT01965925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Ratio of 2:1 subjects will be in the experimental arm receiving modafinil for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
Study: NCT00636818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
Study: NCT00167622

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation
Description: Non invasive mechanical ventilation at least 6 hours per day - if difficult swallowing, tracheal intubation and invasive mechanical ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy and oxygen if needed
Description: oxygen will be delivered via facial mask whenever needed and physiotherapy
Study: NCT01820910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
Study: NCT04098380

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small Bite
Description: the bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Larger bite
Description: the bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
Study: NCT03540095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paravertebral Nerve Block
Description: See arm description
Study: NCT03291327

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Lozenges for Home use

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Lozenges for Home use

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: Lozenges for Home use
Study: NCT04318392

Intervention type: OTHER
Intervention: Breath Analysis
Description: Breath analysis using the ReCIVA device will take place during each study visit.

Intervention type: OTHER
Intervention: Breath Analysis
Description: Breath analysis using the ReCIVA device will take place during each study visit.

Intervention type: OTHER
Intervention: Pulmonary Function Tests
Description: Full Pulmonary Function Tests will be performed at baseline and during each study visit if not performed as part of routine clinical care.

Intervention type: OTHER
Intervention: Blood sampling and storage for genetic analysis
Description: Additional voluntary consent will be sought for blood sampling and storage for genetic analysis at baseline.

Intervention type: OTHER
Intervention: Blood sampling and storage of plasma for metabolomic analysis
Description: Blood sampling and storage of plasma for metabolomic analysis will take place during each study visit.

Intervention type: OTHER
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage will be performed at baseline on all participants undergoing investigation with bronchoscopy or EBUS as part of routine clinical care for investigation of suspected sarcoidosis.

Intervention type: OTHER
Intervention: Sputum Culture
Description: Sputum will be collected during each study visit if the patient can spontaneously expectorate and will be sent for routine microbial analysis as well as metagenomic sequencing.

Intervention type: OTHER
Intervention: Spirometry
Description: Spirometry will be performed on all healthy controls prior to enrolment into the study
Study: NCT04342065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib capsules
Description: received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: received Pregabalin 150mg 2 hours preoperative and the same dose 6 hours postoperative.